» Articles » PMID: 12384339

Biological Cost of Rifampin Resistance from the Perspective of Staphylococcus Aureus

Overview
Specialty Pharmacology
Date 2002 Oct 18
PMID 12384339
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

Resistance determinants that interfere with normal physiological processes in the bacterial cell usually cause a reduction in biological fitness. Fitness assays revealed that 17 of 18 in vitro-selected chromosomal mutations within the rpoB gene accounting for rifampin resistance in Staphylococcus aureus were associated with a reduction in the level of fitness. There was no obvious correlation between the level of resistance to rifampin and the level of fitness loss caused by rpoB mutations. Among 23 clinical rifampin-resistant S. aureus isolates from six countries, only seven different rpoB genotypes could be identified, whereby the mutation 481His-->Asn was present in 21 (91%) of these 23 isolates. The mutation 481His-->Asn, in turn, which confers low-level rifampin resistance on its own, was not shown to be associated with a cost of resistance in vitro. The restriction to distinct mutations that confer rifampin resistance in vivo, as demonstrated here, appears to be determined by the Darwinian fitness of the organisms.

Citing Articles

Unraveling novel mutation patterns and morphological variations in two dalbavancin-resistant MRSA strains in Austria using whole genome sequencing and transmission electron microscopy.

Hotz J, Staudacher M, Schefberger K, Spettel K, Schmid K, Kriz R BMC Infect Dis. 2024; 24(1):899.

PMID: 39223565 PMC: 11367932. DOI: 10.1186/s12879-024-09797-w.


Commensal antimicrobial resistance mediates microbiome resilience to antibiotic disruption.

Bhattarai S, Du M, Zeamer A, M Morzfeld B, Kellogg T, Firat K Sci Transl Med. 2024; 16(730):eadi9711.

PMID: 38232140 PMC: 11017772. DOI: 10.1126/scitranslmed.adi9711.


Rifampicin-resistant RpoB S522L Vibrio vulnificus exhibits disturbed stress response and hypervirulence traits.

Cutugno L, OByrne C, Pane-Farre J, Boyd A Microbiologyopen. 2023; 12(5):e1379.

PMID: 37877661 PMC: 10493491. DOI: 10.1002/mbo3.1379.


Quantifying patient- and hospital-level antimicrobial resistance dynamics in from routinely collected data.

Leclerc Q, Clements A, Dunn H, Hatcher J, Lindsay J, Grandjean L medRxiv. 2023; .

PMID: 36824943 PMC: 9949191. DOI: 10.1101/2023.02.15.23285946.


Performance and drug deposition of kappa-carrageenan microspheres encapsulating ciprofloxacin HCl: Effect of polymer concentration.

Hariyadi D, Purwanti T, Maulydia D, Estherline C, Hendradi E, Rahmadi M J Adv Pharm Technol Res. 2021; 12(3):242-249.

PMID: 34345602 PMC: 8300320. DOI: 10.4103/japtr.JAPTR_197_21.


References
1.
Wichelhaus T, Schafer V, Brade V, Boddinghaus B . Molecular characterization of rpoB mutations conferring cross-resistance to rifamycins on methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1999; 43(11):2813-6. PMC: 89569. DOI: 10.1128/AAC.43.11.2813. View

2.
Guillemot D . Antibiotic use in humans and bacterial resistance. Curr Opin Microbiol. 1999; 2(5):494-8. DOI: 10.1016/s1369-5274(99)00006-5. View

3.
Levin B, Perrot V, Walker N . Compensatory mutations, antibiotic resistance and the population genetics of adaptive evolution in bacteria. Genetics. 2000; 154(3):985-97. PMC: 1460977. DOI: 10.1093/genetics/154.3.985. View

4.
Lenski R . Bacterial evolution and the cost of antibiotic resistance. Int Microbiol. 2000; 1(4):265-70. View

5.
Davies A, Billington O, Bannister B, Weir W, McHugh T, Gillespie S . Comparison of fitness of two isolates of Mycobacterium tuberculosis, one of which had developed multi-drug resistance during the course of treatment. J Infect. 2000; 41(2):184-7. DOI: 10.1053/jinf.2000.0711. View